Actavis , the Swiss generic drugmaker that Watson Pharmaceuticals is taking over, said revenue would rise to more than 2 billion euros ($2.6 billion) this year, driven by patent expiries in Europe and strong demand in the United States . Sales would increase by a double-digit percentage rate in 2012,...
FULL ARTICLE AT Turks and Caicos Free Press